Cargando…
The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study
Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401801/ https://www.ncbi.nlm.nih.gov/pubmed/34441048 http://dx.doi.org/10.3390/medicina57080842 |
_version_ | 1783745637257314304 |
---|---|
author | Algahtani, Fahad Dhafer Elabbasy, Mohamed Tharwat Samak, Mai A. Adeboye, Adeniyi A. Yusuf, Rafeek A. Ghoniem, Mohamed E. |
author_facet | Algahtani, Fahad Dhafer Elabbasy, Mohamed Tharwat Samak, Mai A. Adeboye, Adeniyi A. Yusuf, Rafeek A. Ghoniem, Mohamed E. |
author_sort | Algahtani, Fahad Dhafer |
collection | PubMed |
description | Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required. |
format | Online Article Text |
id | pubmed-8401801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84018012021-08-29 The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study Algahtani, Fahad Dhafer Elabbasy, Mohamed Tharwat Samak, Mai A. Adeboye, Adeniyi A. Yusuf, Rafeek A. Ghoniem, Mohamed E. Medicina (Kaunas) Article Background and Objectives: Preventive, adjunctive and curative properties of lactoferrin have been evaluated since the first wave of severe acute respiratory syndrome coronavirus (SARS-CoV), a viral respiratory disease, emerged 18 years ago. Despite the discovery of new vaccine candidates, there is currently no widely approved treatment for SARS-CoV-2 (COVID-19). Strict adherence to infection prevention and control procedures, as well as vaccines, can, however, prevent the spread of SARS-CoV-2. This study aimed to evaluate the efficacy of lactoferrin treatment in improving clinical symptoms and laboratory indices among individuals with mild to moderate coronavirus disease-19 (COVID-19). Materials and Method: A randomized, prospective, interventional pilot study conducted between 8 July and 18 September 2020 used a hospital-based sample of 54 laboratory-confirmed participants with mild to moderate symptoms of COVID-19. Randomization into a control and two treatment groups ensured all groups received the approved Egyptian COVID-19 management protocol; only treatment group participants received lactoferrin at different doses for seven days. Clinical symptoms and laboratory indices were assessed on Days 0, 2 and 7 after starting treatments. Mean values with standard deviation and one-way analysis of variance with least significant difference of demographic and laboratory data between control and treatment groups were calculated. Results: Our study showed no statistically significant difference among studied groups regarding recovery of symptoms or laboratory improvement. Conclusions: Further research into therapeutic properties particularly related to dosage, duration and follow-up after treatment with lactoferrin in individuals with COVID-19 is required. MDPI 2021-08-19 /pmc/articles/PMC8401801/ /pubmed/34441048 http://dx.doi.org/10.3390/medicina57080842 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Algahtani, Fahad Dhafer Elabbasy, Mohamed Tharwat Samak, Mai A. Adeboye, Adeniyi A. Yusuf, Rafeek A. Ghoniem, Mohamed E. The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title_full | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title_fullStr | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title_full_unstemmed | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title_short | The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study |
title_sort | prospect of lactoferrin use as adjunctive agent in management of sars-cov-2 patients: a randomized pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401801/ https://www.ncbi.nlm.nih.gov/pubmed/34441048 http://dx.doi.org/10.3390/medicina57080842 |
work_keys_str_mv | AT algahtanifahaddhafer theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT elabbasymohamedtharwat theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT samakmaia theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT adeboyeadeniyia theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT yusufrafeeka theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT ghoniemmohamede theprospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT algahtanifahaddhafer prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT elabbasymohamedtharwat prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT samakmaia prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT adeboyeadeniyia prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT yusufrafeeka prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy AT ghoniemmohamede prospectoflactoferrinuseasadjunctiveagentinmanagementofsarscov2patientsarandomizedpilotstudy |